Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00263653

Recruitment Status : Completed

First Posted : December 9, 2005

Last Update Posted : September 21, 2016

Sponsor:

Information provided by (Responsible Party):

GlaxoSmithKline

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a booster dose of the candidate Hib-MenC conjugate vaccine given concomitantly with measles, mumps and rubella (MMR) vaccine, versus Hib-MenC only and MMR only, when given to healthy subjects aged 13 to 14 months who were primed with 3 doses of Hib (as part of a DTPa -containing vaccine) and MenC-CRM197.

Condition or disease	Intervention/treatment	Phase
Haemophilus Influenzae Type b Neisseria Meningitidis	Biological: Haemophilus influenzae type b- and meningococcal (vaccine)	Phase 3

Detailed Description:

This multicenter study is open with respect to the treatment allocation, but double-blind with respect to the Hib-MenC-TT lots (3 lots). Hib-MenC-TT and Priorix™, when given separately, serve as active controls. Two blood samples are taken: before and one month after vaccination. Additional vaccines are offered at study end in order to complete the vaccine schedule recommended in Spain

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	297 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Prevention
Official Title:	Study to Evaluate the Safety, Reactogenicity & Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™, vs Hib-MenC or Priorix™ Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) & MenC-CRM197 Conjugate Vaccines.
Study Start Date :	March 2005
Actual Primary Completion Date :	March 2005
Actual Study Completion Date :	September 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Haemophilus Infections

Genetic and Rare Diseases Information Center resources: Haemophilus Influenzae

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Any grade 3 solicited symptoms (d 0 - 3)

Secondary Outcome Measures :

Sol (d 0-3, local & general), unsol & MMR specific (d 0-42) symptoms. SAEs (whole study). Subjects with Hib-MenC (pre&42 d post vacc): SBA-MenC titers, anti-PRP, -PSC conc. Subjects with MMR (42 d post vacc): anti-measles, -mumps, -rubella seroconversion

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	13 Months to 14 Months (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion criteria:

Healthy male or female between, and including, 13 and 14 months of age.
Previously completed 3-dose primary vaccination with a MenC-CRM197 vaccine, and Hib (given as part of a combined DTPa-containing vaccine) with at least 6 months between the administration of the third doses and the study entry.

Exclusion criteria:

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the study vaccine, or planned use during the study period.
Previous vaccination against OR history of H. influenzae type b (Hib) and/or meningococcal serogroup C disease and/or measles, mumps or rubella OR known exposure to measles, mumps or rubella within 30 days prior to the start of the present study.
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
A family history of congenital or hereditary immunodeficiency.
History of any neurologic disorders or seizures.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine including neomycine

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00263653

Locations


Spain
GSK Investigational Site
Almería, Spain, 04007
GSK Investigational Site
Almería, Spain, 04009
GSK Investigational Site
Antequera/Málaga, Spain, 29200
GSK Investigational Site
Aravaca, Spain, 28023
GSK Investigational Site
Blanes, Spain
GSK Investigational Site
Burgos, Spain, 09005
GSK Investigational Site
Lérida, Spain, 25006
GSK Investigational Site
Madrid, Spain, 28034
GSK Investigational Site
Madrid, Spain, 28035
GSK Investigational Site
Marbella, Spain, 29600
GSK Investigational Site
Mollet del Valles/Barcelona, Spain, 08100
GSK Investigational Site
Pamplona, Spain, 31008
GSK Investigational Site
Sant Adriá de Beyós, Barcelona, Spain, 08930
GSK Investigational Site
Sant Eugenia de Berga, Barcelona, Spain, 08519
GSK Investigational Site
Sevilla, Spain, 41013
GSK Investigational Site
Velez, Malaga, Spain

Sponsors and Collaborators

GlaxoSmithKline

Investigators


Study Director:	GSK Clinical Trials	GlaxoSmithKline

More Information

Additional Information:

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. This link exits the ClinicalTrials.gov site